Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Debt (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Total Debt data on record, last reported at $424342.0 in Q3 2025.

  • For Q3 2025, Total Debt fell 14.17% year-over-year to $424342.0; the TTM value through Sep 2025 reached $424342.0, down 14.17%, while the annual FY2024 figure was $438504.0, 22.78% down from the prior year.
  • Total Debt reached $424342.0 in Q3 2025 per GANX's latest filing, down from $451467.0 in the prior quarter.
  • Across five years, Total Debt topped out at $722542.0 in Q1 2021 and bottomed at $424342.0 in Q3 2025.
  • Average Total Debt over 5 years is $568748.8, with a median of $578274.0 recorded in 2023.
  • Peak YoY movement for Total Debt: decreased 5.89% in 2023, then dropped 22.78% in 2024.
  • A 5-year view of Total Debt shows it stood at $694294.0 in 2021, then decreased by 13.09% to $603393.0 in 2022, then fell by 5.89% to $567850.0 in 2023, then fell by 22.78% to $438504.0 in 2024, then fell by 3.23% to $424342.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $424342.0 in Q3 2025, $451467.0 in Q2 2025, and $427597.0 in Q1 2025.